{"entity":{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","aka":[],"tldr":"The immunologist who ran the Parker Institute from its launch in 2016, building a shared research network across leading US cancer centres; he came from UCSF and now leads a regulatory T cell company.","summary":"Jeffrey Bluestone is a T cell immunologist whose laboratory work on CTLA-4 and on regulatory T cells underpins both checkpoint immunotherapy and cell therapies for autoimmunity. He was the Parker Institute for Cancer Immunotherapy's founding President and Chief Executive Officer from its public launch in 2016, and remains on its board, which lists him as Chief Executive Officer and President of Sonoma BioTherapeutics. His UCSF profile records him as the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Professor Emeritus in the Diabetes Center. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/jeffrey.bluestone"},{"label":"PICI leadership and board","url":"https://www.parkerici.org/about/leadership-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bluestone+JA%5BAuthor%5D"}],"tags":["leadership","immunotherapy"],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor","immunotherapy"],"targets":["ctla4"],"drugs":[],"companies":[],"institutions":["parker-institute","ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founding President and Chief Executive Officer, Parker Institute for Cancer Immunotherapy (2016 to 2021); Chief Executive Officer and President, Sonoma BioTherapeutics","institutionId":"parker-institute","specialisms":["T cell immunology","Immune tolerance and regulatory T cells","Checkpoint biology (CTLA-4)","Research institute leadership"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/jeffrey.bluestone"},{"label":"PICI leadership and board","url":"https://www.parkerici.org/about/leadership-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bluestone+JA%5BAuthor%5D"}],"papers":[{"title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","journal":"Journal of Experimental Medicine","year":2006,"url":"https://doi.org/10.1084/jem.20060772","doi":"10.1084/jem.20060772","note":"Europe PMC author record matched by affiliation"},{"title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","journal":"Nature","year":2008,"url":"https://doi.org/10.1038/nature07336","doi":"10.1038/nature07336","note":"Europe PMC author record matched by affiliation"},{"title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","journal":"Nature Immunology","year":2009,"url":"https://doi.org/10.1038/ni.1774","doi":"10.1038/ni.1774","note":"Europe PMC author record matched by affiliation"}]},"route":"/people/jeffrey-bluestone/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"}],"institution":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}